Fundraising Fox

BioCytics

Huntersville, US · Delaware corporation

biocytics.com

BioCytics conducts translational cancer research, including a project with UNC Charlotte and Carolina BioOncology Institute to study the "dark genome" of cancer cells to identify sequences involved in tumor growth, immune response, and treatment response. Its work spans cell therapy, neoantigens, tumor infiltrating lymphocytes, and clinical research informatics.

BiotechHealthtechMedical Devices

Founders & leadership

JP
John PowderlyPresident & CEO
JP
Jim PowderlyExecutive Officer
MP
Matthew PietrasExecutive Officer
RW
Renaud WarinChief Scientific Officer

Competitors · 8

by search overlap

Companies competing with BioCytics for the same Google search keywords, organic and paid, via search-intersection analysis.

Reported raises · per SEC filings

Form D private placements
$25KraisedMar 2026 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John PowderlyExecutive Officer, Director
  • Jim PowderlyExecutive Officer
Offering amount
$7M
Amount sold
$25K
Minimum investment
$25K
First sale
Jan 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$25KraisedDec 2023 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Don L. JacksonExecutive Officer
  • Jim PowderlyExecutive Officer
  • John PowderlyExecutive Officer, Director
  • Stacy PowderlyExecutive Officer
Offering amount
$4M
Amount sold
$25K
Minimum investment
$25K
First sale
Dec 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$1.4MraisedMar 2023 · 18 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • John PowderlyExecutive Officer, Director
  • Matthew PietrasExecutive Officer
  • Jim PowderlyExecutive Officer
Offering amount
$8M
Amount sold
$1.4M
Minimum investment
$25K
First sale
Feb 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.